Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
A case report
- 27.10.2023
- case report
Erschienen in:
- Verfasst von
- Sophie Roider-Schur
- Sybille Machat
- Leopold Öhler
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 4/2023
Summary
Evaluation of HER2 status and programmed death-ligand 1 (PD-L1) combined positive score (CPS) is mandatory in all patients with HER2-positive metastatic adenocarcinoma of the gastroesophageal junction (GEJ) not only to tailor first-line therapy but also to improve individual survival outcome. However, despite advances in the therapeutic management of metastatic adenocarcinoma of the GEJ, prognosis of these patients remains poor. We report a patient with HER2-positive metastatic adenocarcinoma of the GEJ who showed significant clinical and radiological benefit to HER2-directed therapy in the fifth-line therapeutic setting.
Anzeige
- Titel
-
Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
A case report - Verfasst von
-
Sophie Roider-Schur
Sybille Machat
Leopold Öhler
- Publikationsdatum
- 27.10.2023
- Verlag
- Springer Vienna
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-023-00928-8
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.